Matches in SemOpenAlex for { <https://semopenalex.org/work/W4311162145> ?p ?o ?g. }
Showing items 1 to 71 of
71
with 100 items per page.
- W4311162145 endingPage "1590" @default.
- W4311162145 startingPage "1586" @default.
- W4311162145 abstract "To measure urine malondialdehyde (MDA) and urine peroxynitrite (ONOO) levels in patients with overactive bladder (OAB), and compare them with healthy individuals; to determine the change of those markers in OAB patients prescribed antimuscarinic drugs.An observational study.The Department of Urology, School of Medicine, University of Gaziantep, Gaziantep, Turkey, between August 2021 and February 2022.Patients diagnosed with OAB (Group 1), and healthy controls (Group 2) were compared. Urinary MDA (µmol/L) and ONOO (µmol/L) levels were measured in all participants. The patients diagnosed with OAB were underwent antimuscarinic therapy with propiverine 30 mg. The levels of MDA (µmol/L) and ONOO (µmol/L) were reanalysed during the third month of antimuscarinic therapy. Patients with stress urinary incontinence, neurogenic bladder, pelvic organ prolapse stage ≥3 (POP-Q ≥3), interstitial cystitis (bladder pain syndrome), history of pelvic radiotherapy, symptoms of bladder outlet obstruction, Qmax <10 ml/sec for men and <15 ml/sec for women measured by uroflowmetry, and history of pelvic and incontinence surgery were excluded from the study.There was no difference in the mean age and or gender distribution of the two groups (p=0.166 and p=0.774, respectively). While the mean MDA levels were significantly higher in patients with OAB, (3.34 ± 1.06µmol/L vs. 2.62 ± 1.45µmol/L, p=0.036), no significant change was detected in ONOO levels between the groups (1.03 ± 0.75 µmol/L vs. 0.71 ± 022 µmol/L, p >0.05). Although no significant change was detected in MDA levels after antimuscarinic therapy (3.50 ± 1.19 µmol/L, p=0.529), there was a statistically significant increase in ONOO levels (1.49 ± 1.45 µmol/L, p=0.013).MDA might be used in the diagnosis of OAB, as a biomarker, similar to recent studies. ONOO was evaluated for the first time in the literature for the diagnosis of OAB, unfortunately, no significant outcomes were obtained. In addition, both MDA and ONOO had no role in monitoring antimuscarinic therapy.Overactive bladder, Peroxynitrite, Malondialdehyde." @default.
- W4311162145 created "2022-12-24" @default.
- W4311162145 creator A5015085359 @default.
- W4311162145 creator A5029677900 @default.
- W4311162145 creator A5031430806 @default.
- W4311162145 creator A5055497518 @default.
- W4311162145 creator A5066949324 @default.
- W4311162145 date "2022-12-01" @default.
- W4311162145 modified "2023-10-14" @default.
- W4311162145 title "Peroxinitrite and Malondialdehyde as Biomarkers for Overactive Bladder" @default.
- W4311162145 doi "https://doi.org/10.29271/jcpsp.2022.12.1586" @default.
- W4311162145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36474380" @default.
- W4311162145 hasPublicationYear "2022" @default.
- W4311162145 type Work @default.
- W4311162145 citedByCount "0" @default.
- W4311162145 crossrefType "journal-article" @default.
- W4311162145 hasAuthorship W4311162145A5015085359 @default.
- W4311162145 hasAuthorship W4311162145A5029677900 @default.
- W4311162145 hasAuthorship W4311162145A5031430806 @default.
- W4311162145 hasAuthorship W4311162145A5055497518 @default.
- W4311162145 hasAuthorship W4311162145A5066949324 @default.
- W4311162145 hasBestOaLocation W43111621451 @default.
- W4311162145 hasConcept C126322002 @default.
- W4311162145 hasConcept C126894567 @default.
- W4311162145 hasConcept C141071460 @default.
- W4311162145 hasConcept C142724271 @default.
- W4311162145 hasConcept C204787440 @default.
- W4311162145 hasConcept C2776151105 @default.
- W4311162145 hasConcept C2778401633 @default.
- W4311162145 hasConcept C2778508898 @default.
- W4311162145 hasConcept C2778531004 @default.
- W4311162145 hasConcept C2778941218 @default.
- W4311162145 hasConcept C2780026642 @default.
- W4311162145 hasConcept C2780136519 @default.
- W4311162145 hasConcept C71924100 @default.
- W4311162145 hasConcept C77411442 @default.
- W4311162145 hasConceptScore W4311162145C126322002 @default.
- W4311162145 hasConceptScore W4311162145C126894567 @default.
- W4311162145 hasConceptScore W4311162145C141071460 @default.
- W4311162145 hasConceptScore W4311162145C142724271 @default.
- W4311162145 hasConceptScore W4311162145C204787440 @default.
- W4311162145 hasConceptScore W4311162145C2776151105 @default.
- W4311162145 hasConceptScore W4311162145C2778401633 @default.
- W4311162145 hasConceptScore W4311162145C2778508898 @default.
- W4311162145 hasConceptScore W4311162145C2778531004 @default.
- W4311162145 hasConceptScore W4311162145C2778941218 @default.
- W4311162145 hasConceptScore W4311162145C2780026642 @default.
- W4311162145 hasConceptScore W4311162145C2780136519 @default.
- W4311162145 hasConceptScore W4311162145C71924100 @default.
- W4311162145 hasConceptScore W4311162145C77411442 @default.
- W4311162145 hasIssue "12" @default.
- W4311162145 hasLocation W43111621451 @default.
- W4311162145 hasLocation W43111621452 @default.
- W4311162145 hasOpenAccess W4311162145 @default.
- W4311162145 hasPrimaryLocation W43111621451 @default.
- W4311162145 hasRelatedWork W109990889 @default.
- W4311162145 hasRelatedWork W183249409 @default.
- W4311162145 hasRelatedWork W2002588245 @default.
- W4311162145 hasRelatedWork W2013508761 @default.
- W4311162145 hasRelatedWork W2044552040 @default.
- W4311162145 hasRelatedWork W2065852205 @default.
- W4311162145 hasRelatedWork W2067090596 @default.
- W4311162145 hasRelatedWork W2126309436 @default.
- W4311162145 hasRelatedWork W3038478093 @default.
- W4311162145 hasRelatedWork W4311162145 @default.
- W4311162145 hasVolume "32" @default.
- W4311162145 isParatext "false" @default.
- W4311162145 isRetracted "false" @default.
- W4311162145 workType "article" @default.